Overview

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an opthalmic solution to determine if safe and efficacious for dry eye patients. After a 2-week run-in period, patients will be randomized equally to the PL9643 opthalmic solution or vehicle opthalmic solution administered bilaterally three times a day for 12 weeks. A Data Monitoring Committee will be engaged to review interim data.
Phase:
Phase 3
Details
Lead Sponsor:
Palatin Technologies, Inc
Treatments:
Pharmaceutical Solutions